SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas

Human Pathology

Volumn 46, Issue 11, 2015, Pages 1744-1751

  Bauman, Tyler M ^a   Becka, Alexander J ^b   Sehgal, Priyanka D ^b   Huang, Wei ^c,d   Ricke, William A ^b,c,d  

^a WASHINGTON UNIVERSITY   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Biomarker; Indolent; Multispectral imaging; NF B; Prostate cancer; SIGIRR

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; SINGLE IMMUNOGLOBULIN INTERLEUKIN 1 RELATED RECEPTOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; TIR8 PROTEIN, HUMAN;

ARTICLE; BIOCHEMICAL RECURRENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; FOLLOW UP; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; PROSTATE CARCINOMA; PROSTATE EPITHELIUM CELL; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; TUMOR VOLUME; ADENOCARCINOMA; BLOOD; CANCER GRADING; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

ADENOCARCINOMA; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-1;

EID: 84945439599     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.07.015     Document Type: Article

References (31)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
2. C.M. Tangen, J.R. Faulkner, E.D. Crawford, and et al. Ten-year survival in patients with metastatic prostate cancer Clin Prostate Cancer 2 2003 41 45
3. J.S. Lam, J.T. Leppert, S.N. Vemulapalli, O. Shvarts, and A.S. Belldegrun Secondary hormonal therapy for advanced prostate cancer J Urol 175 2006 27 34
4. E.D. Crawford Understanding the epidemiology, natural history, and key pathways involved in prostate cancer Urology 73 2009 S4 S10
5. M.W. Kattan, T.M. Wheeler, and P.T. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499 1507
6. C. Cordon-Cardo, A. Kotsianti, D.A. Verbel, and et al. Improved prediction of prostate cancer recurrence through systems pathology J Clin Invest 117 2007 1876 1883
7. A.M. De Marzo, E.A. Platz, S. Sutcliffe, and et al. Inflammation in prostate carcinogenesis Nat Rev Cancer 7 2007 256 269
8. O. Ugurlu, M. Yaris, C.V. Oztekin, T.M. Kosan, O. Adsan, and M. Cetinkaya Impacts of antibiotic and anti-inflammatory therapies on serum prostate-specific antigen levels in the presence of prostatic inflammation: a prospective randomized controlled trial Urol Int 84 2010 185 190
9. J.C. Nickel, C.G. Roehrborn, M.P. O'Leary, D.G. Bostwick, M.C. Somerville, and R.S. Rittmaster The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial Eur Urol 54 2008 1379 1384
10. K.S. Sfanos, and A.M. De Marzo Prostate cancer and inflammation: the evidence Histopathology 60 2012 199 215
11. J. Irani, J.M. Goujon, E. Ragni, and et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group Urology 54 1999 467 472
12. E. Thomassen, B.R. Renshaw, and J.E. Sims Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily Cytokine 11 1999 389 399
13. D. Wald, J. Qin, Z. Zhao, and et al. SIGIRR, a negative regulator of toll-like receptor-interleukin 1 receptor signaling Nat Immunol 4 2003 920 927
14. J. Qin, Y. Qian, J. Yao, C. Grace, and X. Li SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms J Biol Chem 280 2005 25233 25241
15. Y. Ben-Neriah, and M. Karin Inflammation meets cancer, with NF-kappaB as the matchmaker Nat Immunol 12 2011 715 723
16. H. Xiao, W. Yin, M.A. Khan, and et al. Loss of single immunoglobulin interleukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice Gastroenterology 139 2010 574 585
17. H. Xiao, M.F. Gulen, J. Qin, and et al. The toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis Immunity 26 2007 461 475
18. C. Garlanda, F. Riva, T. Veliz, and et al. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family Cancer Res 67 2007 6017 6021
19. R. Jin, Y. Yi, F.E. Yull, and et al. NF-kappaB gene signature predicts prostate cancer progression Cancer Res 74 2014 2763 2772
20. W. Huang, K. Hennrick, and S. Drew A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays Hum Pathol 44 2013 29 38
21. S.B. Edge, and C.C. Compton The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 17 2010 1471 1474
22. E.J. Abel, T.M. Bauman, M. Weiker, and et al. Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression Hum Pathol 45 2014 1092 1099
23. T.M. Bauman, P.D. Sehgal, K.A. Johnson, and et al. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues Prostate 74 2014 923 932
24. T.M. Nicholson, P.D. Sehgal, S.A. Drew, W. Huang, and W.A. Ricke Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment Differentiation 85 2013 140 149
25. J. Slezak, M. Truong, W. Huang, and D. Jarrard HP1gamma expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy BMC Cancer 13 2013 148
26. C. Garlanda, C.A. Dinarello, and A. Mantovani The interleukin-1 family: back to the future Immunity 39 2013 1003 1018
27. F. Riva, E. Bonavita, E. Barbati, M. Muzio, A. Mantovani, and C. Garlanda TIR8/SIGIRR is an interleukin-1 receptor/toll like receptor family member with regulatory functions in inflammation and immunity Front Immunol 3 2012 322
28. L.A. O'Neill SIGIRR puts the brakes on toll-like receptors Nat Immunol 4 2003 823 824
29. A. Dunne, and L.A. O'Neill The interleukin-1 receptor/toll-like receptor superfamily: signal transduction during inflammation and host defense Science's STKE: signal transduction knowledge environment 2003 2003 re3
30. V.A. Moyer Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120 134
31. H.B. Carter, A.W. Partin, P.C. Walsh, and et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 30 2012 4294 4296